M0003

M0003 is an investigational oral prokinetic small-molecule drug being studied in combination with stable proton pump inhibitor (PPI) therapy to improve upper gastrointestinal motility and related symptoms in patients with acid-related disorders. In a randomized trial design, patients on a stable PPI dose receive M0003 tablets or placebo three times daily, suggesting that the agent is intended to enhance gastric emptying or esophageal/gastric motility rather than acid suppression itself. The precise molecular target, pharmacology, and sponsoring company have not been publicly disclosed, and no approved medical use has been reported.